AACR to take place in Chicago, USA, from April 25 to 30, with AbClon presenting the latest research findings on AM105
[by Ji, Yong Jun] AbClon announced on March 31 that it will present the latest research findings on its immunotherapy candidate, 'AM105’ (development code), at the annual meeting of the American Association for Cancer Research (AACR).
The AACR annual meeting, scheduled to take place in Chicago, USA, from April 25 to 30, serves as a global platform where experts from the pharmaceutical and biotechnology industries convene to share research findings and explore opportunities for international collaboration.
The dual-antibody treatment candidate AM105 is composed of a novel monoclonal antibody and an affibody, developed using the proprietary 'AffiMab technology.' As a next-generation immunotherapy, AM105 effectively removes cancer cells by simultaneously targeting the 'epithelial growth factor receptor (안전한 바카라 사이트)', a key oncogenic driver in colorectal and lung cancers, and CD137, a T-cell immune stimulator.
Building on the excellent efficacy of AM105, the company will showcase its distinct therapeutic mechanisms and animal model test results. Notably, the presentation will highlight the potential of the AffiMab dual-antibody platform to overcome treatment resistance, emphasizing its superior anticancer effects compared to conventional 안전한 바카라 사이트-targeted treatments. This is anticipated to offer a novel treatment option for patients experiencing decreased efficacy due to resistance to existing therapies.
AM105, a representative antibody-based treatment candidate, demonstrates potential anticancer efficacy not only in patients with limited response to 'cetuximab' and 'panitumumab' but also in those who have developed resistance to 안전한 바카라 사이트 inhibitors such as 'gefitinib' and 'erolotinib'. The company emphasized that these findings suggest the possibility of expanding AM105’s clinical applications to a broader range of anticancer treatments, including those for colorectal and lung cancer.
"We aim to enhance collaboration with global pharmaceutical companies and explore various partnership opportunities, including technology transfer and co-development," an AbClon official said. "We will dedicate our efforts to R&D to establish AM105 as a new hope for patients with refractory cancers who lack effective treatment options due to 안전한 바카라 사이트 resistance."